Mahamaya Lifesciences IPO is an SME public issue opening on November 11, 2025, and closing on November 13, 2025, with a price band of ₹108 to ₹114 per equity share. The company plans to raise approximately ₹70.44 crore through a fresh issue of 56.38 lakh shares and an offer for sale of 5.40 lakh shares. Based in New Delhi, Mahamaya Lifesciences specializes in manufacturing and marketing agrochemical formulations with a focus on technical manufacturing and warehousing expansion. Mahamaya Lifesciences IPO offers investors exposure to the growing agrochemical sector in India with planned capacity expansion and modernization.
₹00
₹114
₹116.00
Expert Opinions
Market sentiment for Mahamaya Lifesciences IPO is cautiously optimistic, with investors showing interest in the agrochemical manufacturing sector amid rising demand for crop protection products. The company’s strengths lie in its WHO-GMP-certified manufacturing facilities, expanding production capacity, and diversified product base catering to domestic and international markets. However, risks include fluctuations in raw material prices, regulatory hurdles, and market competition.
Valuation analysis of Financial Year 2025 highlights Mahamaya Lifesciences IPO with a strong Return on Equity (ROE) of 34.94%, ROCE of 23.15%, and a Net Asset Value (NAV) of ₹27.82, indicating healthy profitability and efficient capital utilization. From a long-term investment perspective, the IPO offers exposure to the growing agrochemical sector driven by increasing agricultural intensification and export potential, making it suitable for investors with a medium to long-term horizon looking to benefit from India’s agri-growth story.
Investor Considerations
Mahamaya Lifesciences IPO investors should consider the company’s solid performance, with revenues increasing steadily to ₹267.17 crore in FY 2025 and a PAT margin of 4.84%. The company operates in the agrochemical sector, which benefits from growing demand for crop protection and soil health products. The IPO valuation reflects a Price to Book Value of 9.40, a moderate Debt to Equity ratio of 1.08, and strengthening fundamentals.
Growth prospects arise from expanded production capacity, diversified product development, and international market focus. Key risks include raw material price volatility, regulatory uncertainties, and competitive industry dynamics. The Mahamaya Lifesciences IPO suits long-term investors aiming to capitalize on India’s agricultural modernization and export upside, while short-term investors should be cautious of sector cyclicality and IPO market volatility.
| Date | GMP | Trend |
|---|---|---|
| 15 Nov 2025 18.54 | ₹00 | --- |
| 14 Nov 2025 19.12 | ₹00 | --- |
| 13 Nov 2025 11.01 | ₹00 | --- |
| 12 Nov 2025 19.43 | ₹00 | --- |
| 10 Nov 2025 20.16 | ₹00 | --- |
| 09 Nov 2025 12.02 | ₹00 | --- |
| 08 Nov 2025 19.35 | ₹00 | --- |
| 07 Nov 2025 11.15 | ₹00 | --- |
| 06 Nov 2025 10.15 | ₹00 | --- |
| 05 Nov 2025 19.28 | ₹00 | --- |
| 04 Nov 2025 19.13 | ₹00 | --- |
FAQs
The Grey Market Premium showed moderate accuracy in predicting Mahamaya Lifesciences IPO’s listing performance. With a final GMP of ₹0, it projected no premium over the issue price of ₹114, while the stock listed slightly higher at ₹116, delivering a gain of 1.75%. This resulted in a small prediction error of 1.75%, where the GMP incorrectly signaled a flat listing but still remained close to the actual outcome, reflecting fair reliability in this case.
Mahamaya Lifesciences IPO Current GMP is ₹00.
Mahamaya Lifesciences IPO Expected Returns is 0.00%.
Mahamaya Lifesciences IPO estimated listing price is ₹114.